✦ LIBER ✦

First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study

✍ Scribed by George D. Demetri; Axel Le Cesne; Sant P. Chawla; Thomas Brodowicz; Robert G. Maki; Bruce A. Bach; Dominic P. Smethurst; Sarah Bray; Yong-jiang Hei; Jean-Yves Blay

Book ID: 116430969
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 818 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2011.12.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Non-pegylated liposomal doxorubicin comb

Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial

✍ S. Del Barco; R. Colomer; L. Calvo; I. Tusquets; E. Adrover; P. Sánchez; J. Rifà 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 220 KB

Brostallicin versus doxorubicin as first

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study

✍ Gelderblom, H.; Blay, J.Y.; Seddon, B.M.; Leahy, M.; Ray-Coquard, I.; Sleijfer, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 758 KB

Motesanib, or open-label bevacizumab, in

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB

Phase 1 European Organisation for Resear

Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx®) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas

✍ O.S. Nielsen; P. Reichardt; T.B. Christensen; D. Pink; S. Daugaard; C. Hermans; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 133 KB

A phase I/randomized phase II, non-compa

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

✍ Roger B. Cohen; Corey J. Langer; George Rajan Simon; Peter David Eisenberg; John 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 387 KB